Loading clinical trials...
Loading clinical trials...
Trastuzumab Rezetecan (SHR-A1811) Versus Chemotherapy of Physician's Choice in Patients With HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis：A Randomized, Prospective, Open-Label Phase II Trial.
Conditions
Interventions
Trastuzumab Rezetecan
Chemotherapy of Physician's Choice
Locations
1
China
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Start Date
March 1, 2026
Primary Completion Date
June 15, 2030
Completion Date
December 30, 2030
Last Updated
March 16, 2026
Lead Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions